A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer.

CONCLUSION: gUDI score can be a useful tool to quantify treatment plans quality also when volumes with different dose-prescription are treated.
PMID: 29945720 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 23, 2018 Category: Radiology Authors: Mambretti M, Romanò C, Marvaso G, Comi S, Cambria R, Ciardo D, Emiro F, Fodor C, Zerini D, Riva G, Petralia G, De Cobelli O, Orecchia R, Cattani F, Jereczek-Fossa BA Tags: Radiother Oncol Source Type: research